3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
171
Sarcoma
63
Dermatologic
28
Thoracic
10
Gastrointestinal
10
Endocrine
7
Lymphoid
6
Breast
6
Other solid neoplasm
4
NET
3
Other hematologic neoplasm
2
Head & Neck
2
Tumor-Agnostic
1
Myeloid
1
Gynecologic
1
Genitourinary
1
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Interventions
fludarabine phosphate
113
Cyclophosphamide
97
Whole-Body Irradiation
82
Mycophenolic Acid
79
fludarabine
74
Tacrolimus
69
Busulfan
68
Azacitidine
62
Peripheral Blood Stem Cell Transplantation
59
Melphalan
48
Cytarabine
48
Antilymphocyte Serum
47
Methotrexate
45
Cyclosporine
45
Filgrastim
39
Imatinib Mesylate
37
Granulocyte Colony-Stimulating Factor
37
Decitabine
35
nilotinib
34
thymoglobulin
31
ruxolitinib
29
Thiotepa
27
Stem Cell Transplantation
23
Clofarabine
22
Alemtuzumab
21
Rituximab
19
Dasatinib
19
Cord Blood Stem Cell Transplantation
19
sargramostim
17
Sirolimus
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Temozolomide
×
Myeloid
×
Clear all
NCT00687323
2017-06-07
TALL
Merck Sharp & Dohme LLC
Phase 2
Completed
47 enrolled
12 charts